Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 25;40(1):6. doi: 10.1007/s10565-024-09840-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — Role of LOXL1 in pan-cancer. (A) The expression levels of LOXL1 in tumor tissues and corresponding normal tissues from UALCAN database. Student’s t test was used for statistical analysis (ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001). (B) The upper panel showed the survival map using the online tool of Gene Expression Profiling Interactive Analysis (GEPIA2). The Kaplan–Meier survival plots in the lower panel indicated that high LOXL1 expression correlated with poor survival outcome in different kinds of cancer (COAD, GBM, KIRC, LGG, LUAD and SARC). (C) Correlation of LOXL1 expression with the infiltration level of immune cells in COAD, BRCA and HNSC. (D) Pearson correlation was analyzed between LOXL1 expression and the infiltration of cancer-associated fibroblast (CAF) (left panel) and endothelial cell (EC) (right panel) based on the EPIC, MCPCOUNTEER, XCELL and TIDE algorithms. (E) Comparison of LOXL1 expression among different immune infiltration subtypes in multiple cancers from the Tumor–Immune System Interactions and Drug Bank (TISIDB) database. (C1, wound healing; C2, IFN-gamma dominant; C3, inflammatory; C4, lymphocyte depleted; C5, immunologically quiet; and C6, TGF-b dominant)